Ultragenyx Pharmaceutical Inc. (62)

Browse by Contract Category

Contracts

Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and John R. Pinion II (Filed With SEC on November 3, 2022)
Amendment No. 2, dated September 13, 2022, to Executive Employment Agreement by and between Ultragenyx Pharmaceutical Inc. and Emil D. Kakkis, M.D., Ph.D (Filed With SEC on November 3, 2022)
Amendment No. 12 to Collaboration and License Agreement, effective as of September 29, 2022, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on November 3, 2022)
Royalty Purchase Agreement by and among Rare Delaware Inc., Ultragenyx Pharmaceutical Inc. and OCM LS23 Holdings LP dated as of July 14, 2022 (Filed With SEC on July 29, 2022)
Second Amendment to Option and License Agreement, dated December 17, 2021, by and between REGENXBIO, Inc. and Ultragenyx Pharmaceutical Inc (Filed With SEC on February 15, 2022)
Second Amendment, dated October 21, 2020, to the Lease Agreement dated December 15, 2019 between Ultragenyx Pharmaceutical Inc. and ARE-San Francisco No. 17, LLC (Filed With SEC on February 12, 2021)
Amendment No. 3, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on November 3, 2022)
Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Dennis Huang (Filed With SEC on November 3, 2022)
Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Karah Parschauer (Filed With SEC on November 3, 2022)
Amendment No. 2, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Thomas Kassberg (Filed With SEC on November 3, 2022)
Amendment No. 2, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Mardi C. Dier (Filed With SEC on November 3, 2022)
Amendment, dated September 13, 2022, to Offer Letter by and between Ultragenyx Pharmaceutical Inc. and Camille Bedrosian, M.D (Filed With SEC on November 3, 2022)
Form of Performance Stock Unit Agreement (2022) (Filed With SEC on May 6, 2022)
Amendment No. 11 to Collaboration and License Agreement, effective as of December 17, 2021 between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on February 15, 2022)
Amendment No. 1 to the Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan (Filed With SEC on November 3, 2021)
Form of Non-Statutory Stock Option Agreement (Annual Grant for Directors) (Filed With SEC on August 3, 2021)
Ultragenyx Pharmaceutical Inc. Deferred Compensation Plan (Filed With SEC on August 3, 2021)
Form of Restricted Stock Unit Agreement (Grant for New Directors) (Filed With SEC on August 3, 2021)
Form of Restricted Stock Unit Agreement (Annual Grant for Directors) (Filed With SEC on August 3, 2021)
Form of Non-Statutory Stock Option Agreement (Grant for New Directors) (Filed With SEC on August 3, 2021)
Open Market Sale Agreement, dated May 7, 2021, by and between Ultragenyx Pharmaceutical Inc. and Jefferies LLC (Filed With SEC on May 7, 2021)
Form of Performance Stock Unit Agreement (2021) (Filed With SEC on May 5, 2021)
Master Services Agreement, dated April 8, 2019, between Ultragenyx Pharmaceutical Inc. and Aenova Haupt Pharma Wolfratshausen GmbH (Filed With SEC on February 12, 2021)
First Amendment, dated September 20, 2020, to the Lease Agreement dated December 15, 2019 between Ultragenyx Pharmaceutical Inc. and ARE-San Francisco No. 17, LLC (Filed With SEC on February 12, 2021)
Lease Agreement, dated December 15, 2019, between Ultragenyx Pharmaceutical Inc. and ARE-San Francisco No. 17, LLC (Filed With SEC on February 12, 2021)
Form of Restricted Stock Unit Agreement (Inducement Plan)(ex-US) (Filed With SEC on February 12, 2021)
Form of Restricted Stock Unit Agreement (Inducement Plan) (Filed With SEC on February 12, 2021)
Form of Non Statutory Stock Option Agreement (Inducement Plan) (ex-US) (Filed With SEC on February 12, 2021)
Form of Non Statutory Stock Option Agreement (Inducement Plan) (Filed With SEC on February 12, 2021)
Employment Inducement Plan (Filed With SEC on February 12, 2021)
Amendment to the License Agreement, dated as of March 22, 2013, between Ultragenyx Pharmaceutical Inc. and Baylor Research Institute (Filed With SEC on February 12, 2021)
License Agreement, dated as of September 20, 2012, between Ultragenyx Pharmaceutical Inc. and Baylor Research Institute (Filed With SEC on February 12, 2021)
Underwriting Agreement, dated as of October 28, 2020, among Ultragenyx Pharmaceutical Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, BofA Securities, Inc., and... (Filed With SEC on November 2, 2020)
Fourth Amended and Restated Amendment to Lease Agreement between Ultragenyx Pharmaceutical Inc. and ARE-MA Region No. 20, LLC (Filed With SEC on October 27, 2020)
Amendment No. 2 dated October 8, 2020 to the Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc. dated as of March 5, 2020, as amended on August... (Filed With SEC on October 13, 2020)
Amendment dated October 9, 2020 to the Offer Letter between Mardi C. Dier and Ultragenyx Pharmaceutical Inc. dated August 28, 2020 (Filed With SEC on October 13, 2020)
Amendment dated as of August 28, 2020 to Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc. dated as of March 5, 2020 (Filed With SEC on September 2, 2020)
Offer Letter between Mardi C. Dier and Ultragenyx Pharmaceutical Inc. dated August 28, 2020 (Filed With SEC on September 2, 2020)
Fourth Amendment, dated as of March 31, 2020, to the Lease Agreement dated as of October 30, 2015 by and between Ultragenyx Pharmaceutical Inc. and ARE-MA Region No., LLC (Filed With SEC on July 31, 2020)
Third Amendment, dated as of July 29, 2019, to the Lease Agreement dated as of October 30, 2015 by and between Ultragenyx Pharmaceutical Inc. and ARE-MA Region No., LLC (Filed With SEC on July 31, 2020)
Equity Purchase Agreement, dated as of June 18, 2019 by and among Ultragenyx Pharmaceutical Inc. and Arcturus Therapeutics Ltd (Filed With SEC on July 31, 2020)
Form of Performance Stock Unit Agreement (2020) (Filed With SEC on May 7, 2020)
Amendment 10 to Collaboration and License Agreement effective as of April 1, 2020 between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on May 7, 2020)
Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc., dated March 5, 2020 (Filed With SEC on March 6, 2020)
Royalty Purchase Agreement, dated as of December 17, 2019, between Ultragenyx Pharmaceutical Inc. and RPI Finance Trust (Filed With SEC on February 14, 2020)
Description of Common Stock (Filed With SEC on February 14, 2020)
Amendment No. 9 to Collaboration and License Agreement, effective December 23, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd (Filed With SEC on February 14, 2020)
Commercial Lease, dated July 2, 2018, between Ultragenyx Pharmaceutical Inc. and 32 Leveroni LLC (Filed With SEC on February 14, 2020)
Office Lease, dated April 19, 2019, between Ultragenyx Pharmaceutical Inc. and Woburn MCB II, LLC (Filed With SEC on February 14, 2020)
Separation Agreement and General Release between Wladimir Hogenhuis, M.D. and Ultragenyx Pharmaceutical Inc., dated November 22, 2019 (Filed With SEC on November 25, 2019)
Amended and Restated Collaboration and License Agreement, dated June 3, 2019, between Ultragenyx Pharmaceutical Inc. and Bayer Healthcare LLC (Filed With SEC on August 2, 2019)
Addendum #2, dated June 19, 2019, to Offer Letter dated May 16, 2017 between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)
Addendum #1, dated August 8, 2017, to Offer Letter dated May 16, 2017 between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)
Offer Letter, dated May 16, 2017, by and between Ultragenyx Pharmaceutical Inc. and Erik Harris (Filed With SEC on August 2, 2019)
Addendum #6 to Standard Lease, effective as of April 29, 2019, by and between Ultragenyx Pharmaceutical Inc. and Condiotti Enterprises, Inc (Filed With SEC on August 2, 2019)
Amendment No. 8 to Collaboration and License Agreement, effective as of July 4, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd. (formerly, Kyowa Hakko Kirin... (Filed With SEC on August 2, 2019)
First Amendment to Option and License Agreement entered into March 18, 2019 between REGENXBIO Inc. and Ultragenyx Pharmaceutical Inc. (as assignee of Dimension Therapeutics, Inc.) (Filed With SEC on May 7, 2019)
Form of Performance Stock Unit Agreement (2019) (Filed With SEC on May 7, 2019)
Amendment No. 7 to Collaboration and License Agreement, entered into as of December 5, 2018, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 7, 2019)
Amendment No. 6 to Collaboration and License Agreement, effective as of February 1, 2019, between Ultragenyx Pharmaceutical Inc. and Kyowa Hakko Kirin Co., Ltd (Filed With SEC on May 7, 2019)
Underwriting Agreement, dated as of February 26, 2019, among Ultragenyx Pharmaceutical Inc. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Merrill Lynch, Pierce, Fenner... (Filed With SEC on March 1, 2019)
Third Lease Amendment to the Lease between Ultragenyx Pharmaceutical Inc. and Rivertech Associates II, LLC, effective December 31, 2018 (Filed With SEC on February 20, 2019)